Monitoring and Living with TRIM22-Related IBD
At a Glance
Children with TRIM22-related IBD need an individualized, long-term monitoring plan that looks beyond symptoms at growth, nutrition, stool and blood inflammation markers, immune health, vaccines, bone health, and emotional well-being; no single test or schedule fits every child.
While the diagnosis provides a name for your child’s condition, it also marks the beginning of a long-term commitment to active monitoring. Living with TRIM22-related IBD is often described as a marathon rather than a sprint. Because this is a Very-Early-Onset IBD (VEO-IBD) with a genetic cause, your child’s care will require frequent “checkpoints” to ensure their growth, nutrition, and immune system remain on track [1][2].
The Monitoring Toolbox: Beyond Symptoms
In children with TRIM22-related IBD, how a child “looks” on the outside doesn’t always match what is happening on the inside. Doctors use a treat-to-target approach, which means they monitor objective markers of inflammation [3]. However, this monitoring must be individualized by age, disease activity, therapy, and nutrition; there is no fixed universal schedule. Examples of monitoring include:
- Growth and Nutrition: Growth is one of the most sensitive indicators of health in VEO-IBD. Your team will track Z-scores (a way of measuring how your child’s height and weight compare to other children their age) [1]. Many children with this condition struggle with anemia (low red blood cells) and low levels of albumin (a protein that can indicate nutritional status or protein loss from gut inflammation). Doctors will check iron studies and selected vitamin levels when clinically indicated [4][5].
- Inflammatory Markers: You will likely become familiar with fecal calprotectin (a stool test) and CRP (a blood test). While useful, these are imperfect. Fecal calprotectin is physiologically higher and more variable in infants, and a normal CRP does not exclude active intestinal inflammation [6][3].
- Repeat Endoscopies: Endoscopies can help assess if true healing is occurring [7][8]. However, repeat endoscopy should be based on clinical targets and the risk/benefit of anesthesia rather than being scheduled universally.
- Bone Health: Chronic inflammation and some medications (like steroids) can weaken a child’s bones. Your team may recommend a DXA scan to monitor bone mineral density [9].
Immune System Stewardship
Because the TRIM22 gene is involved in the immune response, your child’s immune system needs an individualized monitoring plan based on their variant, infection history, and treatment [10].
- Infection Surveillance: Your child’s risk for opportunistic infections depends heavily on their treatment and immune phenotype. Monitoring may include checking immunoglobulins (antibodies) and different types of white blood cells (lymphocytes) as directed by an immunologist [11][12].
- Vaccination Strategy: Vaccinations are a critical but complex topic for children with immune-related IBD. Live vaccines may be contraindicated because of the primary immune disorder itself, not just because of medications. You must have an explicit, immunologist-led plan covering routine non-live vaccination, live vaccines, household contacts, and post-exposure advice. Do not skip or start vaccines without this plan [13].
The Emotional Landscape: Caring for the Caregiver
The psychological toll of raising a child with a rare, unpredictable condition is significant. Parents of children with VEO-IBD often report lower physical and mental health scores compared to parents of healthy children [14].
- “Scan Anxiety”: It is common to feel a surge of anxiety before every lab result or procedure. Qualitative studies show that mothers of children with VEO-IBD find strength in connecting with other “rare” families and receiving clear communication [15].
- The Impact on the Child: While children with VEO-IBD face physical challenges, many show remarkable resilience. Support for their mental health should be part of their long-term care [14].
Looking Toward the Future
Because TRIM22-related IBD was only recently identified, the TRIM22-specific natural history is unknown. General monogenic IBD cohorts report high rates of surgery and medication changes, but this general cohort data is context, not a prediction for an individual child [5][16].
The genetic answer you have today is the key researchers are using to develop the treatments of tomorrow. Your role as a parent is to be the expert on your child, the keeper of their data, and the advocate for their quality of life as this research unfolds [15][17].
A standard monitoring plan must be individualized. Discuss with your team to establish your child’s specific intervals for clinic visits, stool tests, blood work [18][4], and bone health assessments [9][14].
Common questions in this guide
What monitoring does a child with TRIM22-related IBD need?
Can my child have active IBD even if they seem well or their CRP is normal?
How often should repeat endoscopy be done for TRIM22-related IBD?
What vaccine plan does a child with TRIM22-related IBD need?
Could my child need a DXA scan for bone health?
What is known about the long-term outlook for TRIM22-related IBD?
How can parents and children get support while living with this condition?
Get notified when new evidence is published on TRIM22-related inflammatory bowel disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease.
Kelsen JR, Conrad MA, Dawany N, et al.
Inflammatory bowel diseases 2020; (26(6)):909-918 doi:10.1093/ibd/izz214.
PMID: 31560377 - 2
Clinical Phenotypes and Outcomes in Monogenic Versus Non-monogenic Very Early Onset Inflammatory Bowel Disease.
Collen LV, Kim DY, Field M, et al.
Journal of Crohn's & colitis 2022; (16(9)):1380-1396 doi:10.1093/ecco-jcc/jjac045.
PMID: 35366317 - 3
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.
Colombel JF, D'haens G, Lee WJ, et al.
Journal of Crohn's & colitis 2020; (14(2)):254-266 doi:10.1093/ecco-jcc/jjz131.
PMID: 31403666 - 4
Clinical Phenotypes and Genetic Findings in Very-Early-Onset Inflammatory Bowel Disease: A Vietnamese Pediatric Cohort Study.
Nguyen MC, Nguyen TVH, Nguyen L, et al.
Children (Basel, Switzerland) 2026; (13(5)) doi:10.3390/children13050666.
PMID: 42194192 - 5
Infantile and Very Early Onset Inflammatory Bowel Disease: A Multicenter Study.
Guz-Mark A, Aloi M, Scarallo L, et al.
Pediatrics 2024; (154(2)) doi:10.1542/peds.2023-064546.
PMID: 39015095 - 6
Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition.
Weintraub Y, Collen LV, Hussey S, et al.
Inflammatory bowel diseases 2025; (31(8)):2184-2194 doi:10.1093/ibd/izae302.
PMID: 39813158 - 7
Asian-Pacific perspectives on the management of very early-onset inflammatory bowel disease.
Takeuchi I, Arai K, Tanpowpong P, et al.
Intestinal research 2025; (23(4)):405-429 doi:10.5217/ir.2025.00082.
PMID: 41194540 - 8
Histologic alterations are common in Monogenic Disease patients with 'healthy' endoscopy: Results from a GIPAD-GIPPI multicenter study.
Ferro J, Francalanci P, Angerilli V, et al.
Human pathology 2025; (157()):105763 doi:10.1016/j.humpath.2025.105763.
PMID: 40132689 - 9
Risk Factors of Low Bone Mineral Density in Newly Diagnosed Pediatric Inflammatory Bowel Disease.
Ahn MB, Yoo IH
Nutrients 2023; (15(24)) doi:10.3390/nu15245048.
PMID: 38140307 - 10
Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease.
Li Q, Lee CH, Peters LA, et al.
Gastroenterology 2016; (150(5)):1196-1207 doi:10.1053/j.gastro.2016.01.031.
PMID: 26836588 - 11
Inflammatory bowel disease in chronic granulomatous disease: An emerging problem over a twenty years' experience.
Angelino G, De Angelis P, Faraci S, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2017; (28(8)):801-809 doi:10.1111/pai.12814.
PMID: 28981976 - 12
Intersection Between Systemic Autoimmune Diseases, Primary Immunodeficiency and Cancer: a Field in its Infancy.
Sánchez-Ramón S, Ramos-Lisbona AI, Karim MY
Journal of clinical immunology 2026; (46(1)).
PMID: 42350711 - 13
Expert consensus on vaccination in patients with inflammatory bowel disease in Japan.
Ishige T, Shimizu T, Watanabe K, et al.
Journal of gastroenterology 2023; (58(2)):135-157 doi:10.1007/s00535-022-01953-w.
PMID: 36629948 - 14
Pediatric Global Health in Children with Very Early-Onset Inflammatory Bowel Disease.
Holbein CE, Plevinsky J, Patel T, et al.
Journal of pediatric psychology 2021; (46(7)):747-756 doi:10.1093/jpepsy/jsab035.
PMID: 34313785 - 15
Process of empowerment in mothers of children with very-early-onset inflammatory bowel disease: a qualitative study.
Yokoo M, Nomura S, Fukui S, et al.
Intestinal research 2026; (24(1)):151-163 doi:10.5217/ir.2024.00048.
PMID: 39988446 - 16
Clinical Course of Very Early-Onset Inflammatory Bowel Disease.
Cucinotta U, Arrigo S, Dipasquale V, et al.
Journal of pediatric gastroenterology and nutrition 2023; (76(5)):590-595 doi:10.1097/MPG.0000000000003730.
PMID: 36754082 - 17
From Genes to Gut: Understanding Diagnosis and Treatment in Very Early Onset Inflammatory Bowel Disease.
Konys C, Usman Y, Runde J
Pediatric annals 2025; (54(8)):e280-e285 doi:10.3928/19382359-20250612-04.
PMID: 40772941 - 18
European Society of Paediatric Radiology abdominal imaging task force: statement on imaging in very early onset inflammatory bowel disease.
Watson TA, Petit P, Augdal TA, et al.
Pediatric radiology 2019; (49(6)):841-848 doi:10.1007/s00247-019-04375-8.
PMID: 30915515
This page is for informational purposes only and does not constitute medical advice. A child’s gastroenterology, immunology, and genetics team should individualize monitoring, vaccination, and urgent-care plans for TRIM22-related IBD.